VEGFA and Familial prostate cancer: Several strategies have been used to target angiogenesis in prostate cancer including blockade of pro-angiogenic factors like vascular endothelial growth factor (VEGF) via monoclonal antibodies or small molecule inhibitors targeting downstream signaling effector pathways like the VEGF receptor tyrosine kinase pathway [2], [3], [4].